Gilead Sciences (GILD) PT Raised to $123 at RBC Capital
Tweet
Share
E-mailGet Alerts GILD Hot Sheet
Price: $146.64 -2.88%
Rating Summary:
36 Buy, 7 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 26 | Down: 25 | New: 65
Rating Summary:
36 Buy, 7 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 26 | Down: 25 | New: 65
Join SI Premium – FREE
RBC Capital analyst Brian Abrahams raised the price target on Gilead Sciences (NASDAQ: GILD) to $123.00 (from $120.00) while maintaining a Sector Perform rating.
You May Also Be Interested In
- Assembly Bio exercises U.S. profit-share option with Gilead for herpes program
- Royalty Pharma (RPRX) PT Raised to $68 at TD Cowen
- Prada SpA (1913:HK) (PRDSY) PT Lowered to HK$47 at HSBC
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
